Abstract
Primary dysmenorrhoea, defined as painful menstrual cramps in the absence of pelvic pathology, is a common problem in women of reproductive age. Its aetiology and pathophysiology remain largely unknown. Here we performed a two-stage genome-wide association study and subsequent replication study to identify genetic factors associated with primary dysmenorrhoea in a total of 6,770 Chinese individuals. Our analysis provided evidence of a significant (P < 5 × 10^-8) association at rs76518691 in the gene ZMIZ1 and at rs7523831 near NGF. ZMIZ1 has previously been associated with several autoimmune diseases, and NGF plays a key role in the generation of pain and hyperalgesia and has been associated with migraine. These findings provide future directions for research on susceptibility mechanisms for primary dysmenorrhoea. Furthermore, our genetic architecture analysis provides molecular support for the heritability and polygenic nature of this condition.
Introduction
Primary dysmenorrhoea (PD) affects nearly 50% of menstruating women, often causing significant disruption to daily life. Despite its prevalence and known heritability, the specific genetic drivers of the condition have remained largely unknown. Previous studies were often underpowered to yield statistically significant results. This research presents the first large-scale genome-wide association study (GWAS) for PD, identifying two significant genetic risk loci and uncovering underlying biological mechanisms that link immune regulation and pain-processing pathways.
Methodology and Datasets
The researchers employed a robust two-stage GWAS design followed by functional characterization:
- Study Population: A total of 6,770 Chinese women were involved. The discovery stage utilized a meta-analysis of three cohorts (5,324 individuals), followed by a replication stage in an independent cohort (1,446 individuals).
- Analysis: Genotype imputation was performed using the 1000 Genomes Project reference panel. Data from all stages were combined using an inverse-variance fixed-effect model.
- Functional Annotation: To understand the regulatory impact of risk variants, the team integrated data from the Roadmap Epigenome and ENCODE projects, identifying chromatin marks (such as H3K4me3) in tissue-specific regulatory regions.
- Heritability: Restricted Maximum Likelihood (REML) via the GCTA tool was used to estimate the phenotypic variance explained by common autosomal SNPs.
Key Results
The meta-analysis identified two loci that reached genome-wide significance (P < 5 × 10^-8):
- rs76518691 in ZMIZ1: An intronic variant (P = 1.47 × 10^-9) in a gene previously associated with autoimmune diseases like multiple sclerosis and Crohn’s disease.
- rs7523831 near NGF: A variant (P = 1.36 × 10^-8) located downstream of the Nerve Growth Factor gene, which is critical for pain generation and hyperalgesia.
Genetic Architecture and Tissue Specificity
The study estimated that common autosomal SNPs explain approximately 22.9% of the variance in PD susceptibility. Notably, 60.9% of this heritability was attributed to SNPs located in DNaseI hypersensitivity sites (DHSs), suggesting that genetic risk is primarily driven by regulatory variation rather than protein-coding mutations.
Functional analysis highlighted that these risk regions are active in biologically relevant tissues, including mesenchymal stem cells and brain regions involved in pain processing (the cortex and ganglionic eminence). Additionally, while not reaching genome-wide significance individually, the IL1A gene showed a strong aggregate association (P = 2.60 × 10^-5), suggesting shared biological pathways with endometriosis.
Discussion and Future Directions
The identification of loci in ZMIZ1 and near NGF suggests that primary dysmenorrhoea is a polygenic condition involving both immune and neurological signaling. While this study provides a significant step forward, its findings are currently limited to a Chinese population and a relatively modest sample size for a GWAS. Future research should focus on cross-ethnic replication and functional "wet lab" validation to confirm how these variants alter menstrual pain pathways, potentially leading to more targeted relief treatments.
Summary updated